SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Dahlström A)
 

Sökning: WFRF:(Dahlström A) > Omecamtiv mecarbil ...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00007247naa a2200901 4500
001oai:DiVA.org:liu-171398
003SwePub
008201130s2020 | |||||||||||000 ||eng|
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-1713982 URI
0247 a https://doi.org/10.1002/ejhf.20152 DOI
040 a (SwePub)liu
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Teerlink, John R.u Univ Calif San Francisco, USA; Univ Calif San Francisco, USA4 aut
2451 0a Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: GALACTIC-HF baseline characteristics and comparison with contemporary clinical trials
264 c 2020-10-27
264 1b WILEY,c 2020
338 a electronic2 rdacarrier
500 a Funding Agencies|Amgen, Inc.Amgen; Cytokinetics; ServierServier
520 a Aims The safety and efficacy of the novel selective cardiac myosin activator, omecamtiv mecarbil, in patients with heart failure with reduced ejection fraction (HFrEF) is being tested in the Global Approach to Lowering Adverse Cardiac outcomes Through Improving Contractility in Heart Failure (GALACTIC-HF) trial. Here we describe the baseline characteristics of participants in GALACTIC-HF and how these compare with other contemporary trials. Methods and results Adults with established HFrEF, New York Heart Association (NYHA) functional class >= II, ejection fraction <= 35%, elevated natriuretic peptides and either current hospitalization for heart failure or history of hospitalization/emergency department visit for heart failure within a year were randomized to either placebo or omecamtiv mecarbil (pharmacokinetic-guided dosing: 25, 37.5, or 50 mg bid). A total of 8256 patients [male (79%), non-white (22%), mean age 65 years] were enrolled with a mean ejection fraction 27%, ischaemic aetiology in 54%, NYHA class II 53% and III/IV 47%, and median N-terminal pro-B-type natriuretic peptide 1971 pg/mL. Heart failure therapies at baseline were among the most effectively employed in contemporary heart failure trials. GALACTIC-HF randomized patients representative of recent heart failure registries and trials with substantial numbers of patients also having characteristics understudied in previous trials including more from North America (n = 1386), enrolled as inpatients (n = 2084), systolic blood pressure <100 mmHg (n = 1127), estimated glomerular filtration rate <30 mL/min/1.73 m(2) (n = 528), and treated with sacubitril/valsartan at baseline (n = 1594). Conclusions GALACTIC-HF enrolled a well-treated, high-risk population from both inpatient and outpatient settings, which will provide a definitive evaluation of the efficacy and safety of this novel therapy, as well as informing its potential future implementation.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Kardiologi0 (SwePub)302062 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cardiac and Cardiovascular Systems0 (SwePub)302062 hsv//eng
653 a Heart failure; Omecamtiv mecarbil; Cardiac myosin activator; Inotrope; Myotrope; Cardiovascular outcomes trial
7001 a Diaz, Rafaelu Estudios Clin Latino Amer ECLA, Argentina4 aut
7001 a Felker, G. Michaelu Duke Univ, NC USA; Duke Clin Res Inst, NC USA4 aut
7001 a McMurray, John J. V.u Univ Glasgow, Scotland4 aut
7001 a Metra, Marcou ASST Spedali Civili, Italy; Univ Brescia, Italy4 aut
7001 a Solomon, Scott D.u Brigham & Womens Hosp, MA 02115 USA; Harvard Med Sch, MA 02115 USA4 aut
7001 a Adams, Kirkwood F.u Univ N Carolina, NC 27515 USA4 aut
7001 a Anand, Inderu Univ Minnesota, MN USA4 aut
7001 a Arias-Mendoza, Alexandrau Inst Nacl Cardiol, Mexico4 aut
7001 a Biering-Sorensen, Toru Univ Copenhagen, Denmark; Univ Copenhagen, Denmark4 aut
7001 a Bohm, Michaelu Saarland Univ, Germany4 aut
7001 a Bonderman, Dianau Med Univ Vienna, Austria4 aut
7001 a Cleland, John G. F.u Imperial Coll, England; Univ Glasgow, Scotland4 aut
7001 a Corbalan, Ramonu Pontificia Univ Catolica Chile, Chile4 aut
7001 a Crespo-Leiro, Maria G.u Univ A Coruna, Spain4 aut
7001 a Dahlström, Ulfu Linköpings universitet,Avdelningen för diagnostik och specialistmedicin,Medicinska fakulteten,Region Östergötland, Kardiologiska kliniken US4 aut0 (Swepub:liu)ulfda85
7001 a Echeverria Correa, Luis E.u Fdn Cardiovasc Colombia, Colombia4 aut
7001 a Fang, James C.u Univ Utah, UT USA4 aut
7001 a Filippatos, Gerasimosu Univ Athens, Greece4 aut
7001 a Fonseca, Candidau CHLO, Portugal; Univ Nova Lisboa, Portugal4 aut
7001 a Goncalvesova, Evau Comenius Univ, Slovakia4 aut
7001 a Goudev, Assen R.u Queen Giovanna Univ Hosp & Med Univ, Bulgaria4 aut
7001 a Howlett, Jonathan G.u Univ Calgary, Canada; Univ Calgary, Canada4 aut
7001 a Lanfear, David E.u Henry Ford Heart & Vasc Inst, MI USA4 aut
7001 a Lund, Mayannau Middlemore Hosp, New Zealand4 aut
7001 a Macdonald, Peteru St Vincents Hosp Sydney, Australia4 aut
7001 a Mareev, Vyacheslavu Univ Clin Lomonosov Moscow State Univ, Russia4 aut
7001 a Momomura, Shin-ichiu Saitama Citizens Med Ctr, Japan4 aut
7001 a OMeara, Eileenu Montreal Heart Inst, Canada; Univ Montreal, Canada4 aut
7001 a Parkhomenko, Alexanderu Inst Cardiol, Ukraine4 aut
7001 a Ponikowski, Piotru Wroclaw Med Univ, Poland4 aut
7001 a Ramires, Felix J. A.u Univ Sao Paulo, Brazil4 aut
7001 a Serpytis, Pranasu Vilnius Univ, Lithuania4 aut
7001 a Sliwa, Karenu Univ Cape Town, South Africa4 aut
7001 a Spinar, Jindrichu Univ Hosp Brno, Czech Republic4 aut
7001 a Suter, Thomas M.u Univ Bern, Switzerland4 aut
7001 a Tomcsanyi, Janosu St John God Hosp, Hungary4 aut
7001 a Vandekerckhove, Hansu AZ St Lucas, Belgium4 aut
7001 a Vinereanu, Dragosu Univ Med & Pharm Carol Davila, Romania4 aut
7001 a Voors, Adriaan A.u Univ Groningen, Netherlands4 aut
7001 a Yilmaz, Mehmet B.u Dokuz Eylul Univ, Turkey4 aut
7001 a Zannad, Faiezu Univ Lorraine, France4 aut
7001 a Sharpsten, Lucieu Amgen Inc, CA 91320 USA4 aut
7001 a Legg, Jason C.u Amgen Inc, CA 91320 USA4 aut
7001 a Abbasi, Siddique A.u Amgen Inc, CA 91320 USA4 aut
7001 a Varin, Claireu Servier, France4 aut
7001 a Malik, Fady I.u Cytokinetics Inc, CA USA4 aut
7001 a Kurtz, Christopher E.u Amgen Inc, CA 91320 USA4 aut
7102 a Univ Calif San Francisco, USA; Univ Calif San Francisco, USAb Estudios Clin Latino Amer ECLA, Argentina4 org
7730 t European Journal of Heart Failured : WILEYg 22:11, s. 2160-2171q 22:11<2160-2171x 1388-9842x 1879-0844
8564 u https://liu.diva-portal.org/smash/get/diva2:1504676/FULLTEXT01.pdfx primaryx Raw objecty fulltext:print
8564 u https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/ejhf.2015
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-171398
8564 8u https://doi.org/10.1002/ejhf.2015

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy